Imatinib administration in two patients with liver metastases from GIST and severe jaundice

Research output: Contribution to journalArticle

Abstract

Imatinib is the only effective and approved systemic therapy for the treatment of patients with advanced gastrointestinal stromal tumours (GISTs). Although metastases from GISTs most commonly involve the liver, yielding hyperbilirubinaemia, very few data on imatinib administration in subjects with jaundice are available. We provide evidence that imatinib tolerability was not adversely affected by jaundice in two patients with advanced GIST.

Original languageEnglish
Pages (from-to)1403-1404
Number of pages2
JournalBritish Journal of Cancer
Volume89
Issue number8
DOIs
Publication statusPublished - Oct 20 2003

Keywords

  • Glivec
  • Hyperbilirubinaemia
  • Imatinib
  • Jaundice

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Imatinib administration in two patients with liver metastases from GIST and severe jaundice'. Together they form a unique fingerprint.

  • Cite this